Inotiv (Inotiv) Short Interest

View and export this data going back to 1997. Start your Free Trial

What is Inotiv Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.

Competitive Comparison of Inotiv's Short Interest

For the Diagnostics & Research subindustry, Inotiv's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Inotiv's Short Interest Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Inotiv's Short Interest distribution charts can be found below:

* The bar in red indicates where Inotiv's Short Interest falls into.

Inotiv (Inotiv) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Inotiv Inc (NAS:NOTV) » Definitions » Short Interest

Comparable Companies

Traded in Other Exchanges

BS50:Germany

Address

2701 Kent Avenue, West Lafayette, IN, USA, 47906

Website

https://www.inotivco.com

Inotiv Inc is a pharmaceutical development company specializing in nonclinical and analytical drug discovery and development services to the pharmaceutical, chemical, and medical device industries. It operates in two segments; Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). Through the DSA segment, it supports the discovery, nonclinical development, and clinical development needs of researchers and clinicians for small molecule drug candidates, as well as biotherapeutics and biomedical devices. Through the RMS segment, it offers access to a wide range of small and large research models for basic research and drug discovery and development, as well as specialized models for specific diseases and therapeutic areas. It earns maximum revenue from RMS Segment.

Executives

John Gregory Beattie	officer: Chief Operating Officer	C/O BIOANALYTICAL SYSTEMS, INC., 2701 KENT AVENUE, WEST LAFAYETTE IN 47906
Michael Garrett	officer: Chief Commercial Officer	250 PEHLE DRIVE, SUITE 601, SADDLE BROOK NJ 07663
Andrea Castetter	officer: SVP, Gen. Counsel & Secretary	2701 KENT AVENUE, WEST LAFAYETTE IN 47906-1382
Mary Theresa Coelho	director	52 SUNRISE PARK ROAD, NEW HAMPTON NY 43017
John E Sagartz	director, officer: Chief Strategy Officer	19 WORTHINGTON ACCESS DRIVE, MARYLAND HEIGHTS MO 63043
David Landman	director	2701 KENT AVENUE, WEST LAFAYETTE IN 47906-1382
Robert Jr. Leasure	director, officer: President and CEO	C/O BIOANALYTICAL SYSTEMS, INC., 2701 KENT AVENUE, WEST LAFAYETTE IN 47906-1382
Beth Taylor	officer: Chief Financial Officer	3000 KENT AVENUE, SUITE A1-100, WEST LAFAYETTE IN 47906
Jeffrey Arthur Krupp	officer: Chief Human Resources Officer	2701 KENT AVENUE, WEST LAFAYETTE IN 47906-1382
William D Pitchford	officer: Chief Human Resources Officer	1000 SAGAMORE PARKWAY SOUTH, LAFAYETTE IN 47905
R Matthew Neff	director	535 N. COLLEGE DRIVE, CARMEL IN 46032
Jeffrey Brennan Freeman	officer: VP-Finance & Corp. Controller	2701 KENT AVENUE, WEST LAFAYETTE IN 47906-1382
Davis Gregory Cole	director	C/O BIOANALYTICAL SYSTEMS, INC., 2701 KENT AVENUE, WEST LAFAYETTE IN 47906
Nigel Brown	director	250 PEHLE AVENUE, SUITE 600, SADDLE BROOK NJ 07663
Scott Cragg	director	660 MADISON AVENUE, NEW YORK NY 10065